The Heart Institute of Japan Candesartan Randomized trial for Evaluation in Coronary Artery Disease

The Heart Institute of Japan Candesartan Randomized trial for Evaluation in Coronary Artery Disease - HIJ-CREATE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000790

Enrollment

2030

Registered

2007-11-07

Start date

2001-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Candesartan-based therapy without any angiotensin-converting enzyme inhibitors Non-ARB based standard therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Coronary angiographically documented patients with coronary artery disease and hypertension

Exclusion criteria

Exclusion criteria: Patients with socondary hypertension hypertrophic obstructive cardiomyopathy Acute myocardial infarction (withih 7 days) cerebrovascular disease within 3 months serum Creatinine >=2.0mg/dl hyperkalemia

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the present study was the time to the first major adverse cardiovascular events.	—

Secondary

Measure	Time frame
The major secondary endpoints included the incidence of coronary revascularization and new-onset diabetes.	—

Countries

Japan

Contacts

Public ContactHiroshi Ogawa

The Heart Institute of Japan, Tokyo Women's Medical University Cardiology

mogawa@hij.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026